What Летрозол-Тева Treats: Main Uses and Benefits

The primary role of Летрозол-Тева is considered relevant in contexts involving heightened systemic burden for postmenopausal women diagnosed with breast cancer that is sensitive to female hormones (hormone receptor-positive). Its therapeutic value is related to addressing the underlying systemic imbalance that fuels the condition. The medication is commonly used across multiple phases of treatment.

---

Key Therapeutic Contexts and Benefits

This medication is applied in clinical settings that involve early-stage disease, aiming to manage the biological risk of the cancer returning (recurrence) in the future. By maintaining long-term control, it may assist with managing the biological risk of recurrence and helps maintain a sense of stability when symptoms are more noticeable. The medication is commonly used across conditions presenting with systemic or localized discomfort where additional symptomatic support is needed, including adjuvant, extended adjuvant, and first-line advanced therapy.

The medication is applied in contexts where temporary assistance in symptom stabilization is needed, such as in a neoadjuvant setting, where it may assist with addressing the size of large primary tumors before surgery. This use is helpful in situations requiring additional symptomatic assistance.

Quick Fact: Relief for Systemic Disease Burden Летрозол-Тева is relevant for easing challenging symptoms associated with conditions marked by increased physiological stress across both early and advanced stages of the disease.

Regulatory References

1. DailyMed (NIH) label for Letrozole tablets

Eligibility Map: Who can and cannot use Летрозол-Тева — Official Regulatory Information

The use of Летрозол-Тева (Letrozole) is strictly governed by regulatory documentation regarding patient populations and physiological status.

---

Populations for Whom Use is Allowed

The medicine is intended for use only in postmenopausal women, including those who are naturally or artificially postmenopausal. The patient's postmenopausal endocrine status must be confirmed before treatment initiation, often requiring measurement of specific hormone levels.

Populations for Whom Use is Contraindicated

The following groups must not use Летрозол-Тева, as stated in the official product labeling:

• Premenopausal women and women of child-bearing potential.
• Women who are pregnant or breastfeeding (lactating).
• Patients with a known hypersensitivity to Letrozole or any other component of the tablet.

---

Condition-Specific and Age-Related Rules

Condition/Group	Regulatory Status
Severe Hepatic Impairment (Child-Pugh C)	Requires close supervision; exposure to Letrozole is increased.
Severe Renal Impairment ( CrCl <10 mL/min)	Insufficient data are available; risk/benefit must be carefully considered.
Pediatric Population (le 17 years)	Not recommended; safety and efficacy have not been established.
Older Adults (ge 65 years)	No dosage adjustment is required.

---

Interactions with other medicines and products

Official regulatory information describes specific interaction patterns for Letrozole that relate primarily to metabolic pathways and pharmacodynamic effects.

Interaction-Related Restrictions

Co-administration with estrogen-containing medications, including hormone replacement therapy (HRT) or oral contraceptives, should be avoided. This restriction is due to the risk of counteracting the anti-estrogen action of Letrozole. The simultaneous use of Tamoxifen is also advised against, as regulatory studies document a substantial reduction in the plasma concentration of Letrozole with this combination.

Metabolic and Pharmacokinetic Interactions

Letrozole is documented in in vitro studies as a strong inhibitor of Cytochrome P450 CYP2A6 and a moderate inhibitor of CYP2C19. Caution is indicated when co-administering Letrozole with medicinal products whose clearance is highly dependent on these enzymes and which possess a narrow therapeutic index. In contrast, studies with Cimetidine and Warfarin showed no clinically significant effect on the pharmacokinetics of Letrozole, indicating no need for special timing or dosage adjustments for these specific combinations.

Food and Population-Specific Notes

Letrozole may be taken with or without food, as food does not significantly affect its absorption. Regulatory documents also note that patients with severe hepatic impairment exhibit approximately a two-fold increase in systemic exposure (AUC) to Letrozole, a factor that affects overall interaction sensitivity in this population.

Targeted Inhibition of the Aromatase Enzyme

This mechanism focuses on the drug's molecular action as a highly selective, non-steroidal competitive inhibitor of the Aromatase enzyme (CYP19A1). By binding reversibly to the enzyme's active site, Letrozole blocks the essential last step in the estrogen biosynthesis pathway, preventing the conversion of androgen precursors into estrogens. This action modifies the upstream molecular steps of a key endocrine signaling cascade.

---

Modulation of Systemic Estrogen Signaling

The primary physiological consequence of enzyme inhibition is a significant reduction in the concentration of circulating estradiol (E2) and estrone. This creates a state of systemic estrogen deprivation, which eliminates a hormonal signal that drives proliferation and growth in estrogen-sensitive tissues. The application of this mechanism is highly constrained by the target tissue expressing the Estrogen Receptor ( ER+) and is primarily effective in physiological states where peripheral tissues are the main source of estrogen.

Administration Guidelines for Летрозол-Тева (Letrozole)

Летрозол-Тева is administered according to a standardized protocol, with the objective of maintaining consistent drug exposure. The medication is provided as a 2.5 mg film-coated tablet and is taken orally.

Administration Scope	Instruction
Standard Daily Dose	2.5 mg administered once daily.
Timing & Intake	May be taken without regard to meals. Should be swallowed whole at approximately the same time each day.
Missed Dose Rule	If a dose is missed, it should be skipped if the next dose is due shortly. Do not take two doses at once.
Duration Pattern	In the adjuvant setting, treatment typically continues for five years. For advanced disease, administration continues until tumor progression is evident.
Hepatic Adjustment	For patients with cirrhosis and severe hepatic impairment (Child-Pugh C), the recommended administration is 2.5 mg every other day.

Instruction Classifications (High-Level)

• Administration Method Type: Oral
• Frequency Pattern: Once daily
• Population Adjustments: Required for severe hepatic impairment.

The administration follows a daily intake of a fixed dose to ensure steady, continuous inhibition. This usage structure defines the long-term commitment and the specific conditions, such as severe liver impairment, that require a modification of the administration frequency.

This section provides a factual overview of the clinical research conducted for the active ingredient in Летрозол-Тева, Letrozole. This information is based on the structure and content of the major studies and does not offer personal medical advice or predictions.

---

## Evidence for use in Early-Stage Breast Cancer (Adjuvant Therapy)

Large-scale, international Randomized Controlled Trials (RCTs) were conducted to evaluate the use of this medicine after a woman has had surgery for early-stage hormone receptor-positive breast cancer. These studies were designed to monitor the health status of postmenopausal women over many years, comparing the outcomes of those who received Letrozole against those who received other types of hormonal therapy.

The primary measures researchers studied were Disease-Free Survival (DFS), which documented the time to recurrence events, and Overall Survival (OS). Findings from these multi-year trials reported measurements of recurrence events and documented the observed time intervals in comparison to Tamoxifen monotherapy. What remains uncertain is the long-term impact on overall survival in the context of patients switching treatments during the trial period.

---

## Evidence for use in Extended Adjuvant Therapy

Research has also explored the role of Letrozole after a postmenopausal woman has already completed five years of prior anti-hormonal therapy. These were typically Placebo-Controlled Randomized Trials (RCTs). The studies explored outcomes related to physical discomfort and monitored Disease-Free Survival (DFS) and the incidence of a new cancer in the opposite breast. Trials documented the observed patterns related to recurrence rates between the group receiving Letrozole and the group receiving placebo.

What remains uncertain is the optimal total duration for this extended treatment approach. While initial data from these trials provided early insight, the follow-up durations were limited at the time, which meant that long-term safety and survival patterns required further years of observation to be fully characterized.

---

## What is Still Uncertain About the Research for Летрозол-Тева

While a significant volume of research exists, there are still areas where certainty remains low. Long-term effects are not fully established across all subgroups, and follow-up durations were limited in the initial reports for some key studies. The study results reflect the specific conditions under which they were conducted, and findings describe group patterns, not personal outcomes. Furthermore, evidence quality varies across studies, and data for certain pre-existing conditions remain insufficient.

Key Studies & References Letrozole (Femara) tablet, film coated, Daiichi Sankyo, Inc. (Official US Prescribing Information)

Common questions about Летрозол-Тева (FAQ)

Q: What does the term 'adjuvant therapy' mean in the context of this drug?

A: Adjuvant therapy is a term used in this context to describe the use of the drug after a patient has had surgery for early breast cancer. The purpose of this treatment, as indicated by clinical trials, is to reduce the risk of the cancer potentially returning in the future.

Q: Can men use Летрозол-Тева?

A: The official product indications state that letrozole is approved for the treatment of certain types of breast cancer in postmenopausal women only. Therefore, the drug is not indicated for use in men.

Q: Is hair thinning or hair loss a common concern while using this medicine?

A: Alopecia, which refers to hair loss or thinning, is listed as a common side effect in the regulatory safety information. In one major adjuvant trial, this effect was reported in 3.4% of patients.

Q: Can Летрозол-Тева affect mood or cause depressive symptoms?

A: Official regulatory safety information lists depression as a common adverse reaction, reported in 4.9% of patients in one major trial. Other mood-related effects such as anxiety and irritability have also been reported uncommonly in the safety profile.

Q: Is weight gain a commonly reported side effect of Летрозол-Тева?

A: Weight increase is a commonly reported side effect, according to data from clinical trials. In one adjuvant trial, this effect was reported in 12.9% of patients.

Q: Can I drink alcohol while taking Летрозол-Тева?

A: Official guidance states there is no evidence that drinking alcohol causes specific safety problems or interactions when taking letrozole. However, individuals should be aware that alcohol intake might worsen some common side effects, such as hot flashes, nausea, or dizziness.

Q: Does Летрозол-Тева interact with common over-the-counter stomach medicines?

A: Regulatory drug interaction studies have examined the use of letrozole with Cimetidine, a common drug used to reduce stomach acid. These studies showed no clinically significant effect on how the body processes letrozole.

Q: How long does it typically take for Летрозол-Тева to start working based on research?

A: Pharmacological studies show that letrozole achieves its primary action, which is maximal estrogen suppression, relatively quickly. This significant suppression (75% to 95% reduction from baseline) is typically observed within two to three days of starting daily dosing.

Q: How often do people typically need medical check-ups or tests while on this medication?

A: Regulatory safety information indicates that formal assessment and monitoring of bone mineral density is important during treatment. Monitoring of serum cholesterol is also a point for clinical consideration.

Q: Is Летрозол-Тева classified as a controlled substance?

A: According to official governmental classifications, letrozole is not classified as a controlled substance under the U.S. Controlled Substances Act (CSA). It is supplied as a prescription-only medicine.

Q: Does Летрозол-Тева cause hot flashes more often than similar drugs?

A: Official study data comparing letrozole to tamoxifen showed a slightly lower incidence of hot flashes for letrozole patients (33.5%) compared to tamoxifen patients (38.0%). Both hormonal therapies commonly report this effect, which is why they are highlighted in the safety profile. General regulatory guidance suggests discussing all potential side effects with a healthcare provider.

Q: Are there any specific foods or supplements that interact with Летрозол-Тева?

A: Official product information states that the drug's absorption is not affected by food, meaning it can be taken with or without a meal. Co-administration with the supplement DHEA may reduce the effectiveness of both products. It is consistent with regulatory principles to discuss the use of any supplements with a healthcare professional.

Q: Can I take Летрозол-Тева if I also have high blood pressure?

A: High blood pressure, or hypertension, is listed as a common adverse reaction in the regulatory safety profile of the drug. Official guidance indicates that pre-existing conditions and adverse effects are important points for patient-physician discussion.

Q: Does skipping a dose affect the overall effectiveness of the multi-year treatment?

A: The drug is taken daily to maintain a steady-state level in the body. The official administration rule advises that a missed dose should be skipped if the next dose is due shortly, and states not to take two doses at once. No information is provided on the effect of one missed dose on the overall long-term treatment effectiveness.

Q: Can I split or crush Летрозол-Тева tablets if they are hard to swallow?

A: The regulatory administration rules specify that Летрозол-Тева tablets are film-coated and must be swallowed whole with a glass of water. This instruction is necessary to ensure the drug is absorbed correctly, as designed by the manufacturer.

Q: When is the best time of day to take Летрозол-Тева?

A: Official administration guidelines state the drug should be taken once daily at approximately the same time each day. No specific time of day (such as morning or evening) is officially recommended as being 'best' for patient tolerance or efficacy.

How to Store and Dispose of Letrozole Tablets

The storage and disposal of Letrozole tablets, including Летрозол-Тева, must strictly follow the requirements documented in official regulatory labeling to ensure product stability and environmental safety.

Official Storage Conditions

Requirement	Official Instruction
Temperature	Store at a temperature below 30 C
Protection	Protect from heat and moisture
Container	Keep the tablets in the original container and outer carton
Child Safety	Keep out of the sight and reach of children

Disposal Instructions

To prevent environmental contamination, the product must not be thrown away via wastewater or household waste.

Any unused or expired tablets must be returned to a pharmacist for proper, regulated disposal, which is required by official guidance.